Payment overview · 2025
General Payments
$219.39
12 reported records · 8 companies
Healthcare provider profile · identity verified
Thomas Carl Pendleton, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BESSEMER, AL · NPI 1265543482
Verified facts
What the public records show
CMS Open Payments records show Thomas Carl Pendleton, M.D. received $219.39 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 36.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.20 | 36.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.55 | 13.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.39 | 9.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.00 | 9.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.80 | 9.0% | 1 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $16.27 | 7.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.70 | 7.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.48 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $219.39 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.60 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.55 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| ZEVTERA Normalized: zevtera |
Drug | La Jolla Pharmaceutical Company | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 72 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1014 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 418 | 114 |
| Alprazolam | Alprazolam | 368 | 37 |
| Montelukast Sodium | Montelukast Sodium | 298 | 86 |
| Losartan Potassium | Losartan Potassium | 280 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 256 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 74 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 190 | 60 |
| Gabapentin | Gabapentin | 184 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 176 | 51 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 171 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 46 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 144 | 43 |
| Potassium Chloride | Potassium Chloride | 137 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 41 |
| Metformin Hcl | Metformin Hcl | 129 | 39 |
| Meloxicam | Meloxicam | 124 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 107 | 30 |
| Glimepiride | Glimepiride | 100 | 30 |
| Alendronate Sodium | Alendronate Sodium | 98 | 27 |
| Januvia | Sitagliptin Phosphate | 96 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 30 |
| Ozempic | Semaglutide | 92 | 16 |
| Furosemide | Furosemide | 91 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 12 |
| Omeprazole | Omeprazole | 86 | 29 |
| Finasteride | Finasteride | 82 | 22 |
| Terazosin Hcl | Terazosin Hcl | 82 | 23 |
| Carvedilol | Carvedilol | 75 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 26 |
| Colchicine | Colchicine | 73 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 72 | 21 |
| Eliquis | Apixaban | 72 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 13 |
| Lorazepam | Lorazepam | 64 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 43 |
| Clonazepam | Clonazepam | 58 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 15 |
| Trazodone Hcl | Trazodone Hcl | 58 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | suppressed |
| Myrbetriq | Mirabegron | 49 | 11 |
| Tramadol Hcl | Tramadol Hcl | 49 | suppressed |
| Tradjenta | Linagliptin | 48 | 13 |
| Diazepam | Diazepam | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 15 |
| Metformin Hcl Er | Metformin Hcl | 44 | 18 |
| Ketoconazole | Ketoconazole | 41 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Klor-Con M20 | Potassium Chloride | 35 | 11 |
| Lactulose | Lactulose | 35 | suppressed |
| Lisinopril | Lisinopril | 34 | 12 |
| Prednisone | Prednisone | 33 | suppressed |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 13 |
| Labetalol Hcl | Labetalol Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 19 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 12 |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 13 |
| Estradiol | Estradiol | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 12 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 12 |
| Sucralfate | Sucralfate | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 15 |
| Cilostazol | Cilostazol | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 12 |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Zonisamide | Zonisamide | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Desloratadine | Desloratadine | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $219.39 · 12 records | Novo Nordisk Inc | Dexcom G6 Transmitter, ELIQUIS, KRYSTEXXA, MOUNJARO, Ozempic, RELISTOR, Wegovy, YUPELRI, ZEVTERA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error